Treatment Of Steroid-Refractory Acute GVHD With Mesenchymal Stem Cells Improves Outcomes In Pediatric Patients; Results Of The Pediatric Subset In A Phase III Randomized, Placebo-Controlled Study

Successful treatment of steroid-refractory aGVHD (SR-GVHD) following allogeneic hematopoietic cell transplantation remains a significant challenge. Because of their immunomodulatory properties and safety profile, adult mesenchymal stem cells (MSCs) have been proposed as a treatment for SR-GVHD. Intravenous allogeneic MSC therapy (Prochymal®) for SR-GVHD was independently evaluated in the pediatric subset of a double-blind, placebo-controlled study (Protocol 280).